Hyperliquid Strategies (NASDAQ:PURR) reported a profitable fiscal third quarter, with results driven primarily by appreciation in the HYPE token and continued staking revenue, executives said on the company’s third-quarter 2026 earnings call.
CEO David Schamis said the company remains “by far the l
Let's delve into the US markets on Friday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
Hyperliquid’s (NASDAQ:PURR) oil perpetual futures contract hit $1.7 billion in daily trading volume as non-crypto traders sought 24/7 oil exposure during the Iran war
BitMEX co-founder Arthur Hayes says he has re-entered his Hyperliquid (NASDAQ:PURR) trade, predicting the asset could surge more than fourfold if the p
As pharmaceutical companies race to develop treatments for metabolic dysfunction–associated steatohepatitis (MASH) and related steatotic liver disease (SLD), one critical piece of the healthcare puzzle is drawing increasing attention: how to diagnose and monitor millions of patients at scale . While most investor focus remains on drug developers, ENDRA Life Sciences (NASDAQ: NDRA) is positioning itself on the infrastructure side of the emerging MASH ecosystem with its innovative TAEUS® (Thermo-Acoustic Enhanced UltraSound) liver imaging technology.
